CN204192798U - A kind of degradable amniotic membrane lacrimal passage recovery support - Google Patents
A kind of degradable amniotic membrane lacrimal passage recovery support Download PDFInfo
- Publication number
- CN204192798U CN204192798U CN201420663134.7U CN201420663134U CN204192798U CN 204192798 U CN204192798 U CN 204192798U CN 201420663134 U CN201420663134 U CN 201420663134U CN 204192798 U CN204192798 U CN 204192798U
- Authority
- CN
- China
- Prior art keywords
- amniotic membrane
- rack body
- degradable
- lacrimal passage
- recovery support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The utility model discloses a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body, described rack body is made up of degradable biomaterial, and one end of described rack body is connected with medical suture, and the outer wall of described rack body is enclosed with bioamnion.This utility model structure is simple, has slowed down the degradation time of amniotic membrane, and after outer field amniotic membrane degraded, part amniotic membrane degradation solution is attached on rack body, continues the effect playing amniotic membrane, meets the demand for the treatment of cycle; The rack body that degradable biomaterial is made remains the elasticity of silica gel tube, hot strength and tension force, slowly can degrade voluntarily, do not need tube drawing after treatment cycle, can not cause damage and secondary blocking to lacrimal passage tissue.
Description
Technical field
This utility model relates to field of biomedicine technology, especially relates to a kind of degradable amniotic membrane lacrimal passage recovery support.
Background technology
Lacrimal Passage Block (lacrimal duct obstruction diseases, one group of disease that what LDOD) refer to that a variety of causes causes take obstructed lacrimal passage as pathological characters, the tear that overflows is main clinical manifestation, ophthalmology common disease and frequently-occurring disease, traditional Therapeutic Method is External dacryocystorhinostomy (externaldacryocystorhinostomy, EDCR), it is large to there is wound surface in the method, and face leaves wound scar, affects defect attractive in appearance; First domestic scholars Zhou Bing in 1994 etc. introduce field of ophthalmology nasal endoscopes, and under reporting nasal endoscopes, dacryocystorhinostomy (intranasal endoscopic dacryocystorhinostomy, IEDCR) succeeds.After this scientists is by the improvement constantly to operating theater instruments, to the improvement of operation method, success rate of operation is improved constantly.However, that encounters when IEDCR faces from outside operation equally is ostomy little, the problem that postoperative granulation tissue, scar tissue block again, and after obstructed lacrimal passage spy is logical, in lacrimal passage, indwelling intubate can isolate wound surface, expands lacrimal passage, avoid adhesion and cicatricial contracture; But also can stimulate granulation tissue hyperplasia in lacrimal passage simultaneously, suppress the reparation of wound surface epithelial cell, tear puncta, make lacrimal ductule sphincter unable, hinder the drawbacks such as postoperative administration.
In the past conventional indwelling intubate has silica gel tube, segmental epidural catheter etc., and find in clinical practice, silicone stent can cause damage because of drawing friction to lacrimal passage tissue, even due to lacrimal passage adhesion and secondary blocks lacrimal passage; Segmental epidural catheter quality is hard, poor flexibility, part patient cannula difficulty in art, and be fixed on face due to one end of pipe, impact beauty treatment, the phenomenon that postoperative easy appearance is pulled out unintentionally, deviate from, some patients easily causes lacrimal ductule and chips and cause lacrimal passage permanent obstructed.
The first generation amniotic membrane lacrimal passage recovery support developed by Jiangxi RuiJi Biotechnology Co., Ltd, the curved structure of lacrimal passage can be adapted to, avoid causing damage and adhesion and the generation that causes secondary to block because of drawing friction to lacrimal passage tissue, simultaneously, because the specific function of amniotic membrane has good therapeutic efficiency to pathological tissues, have and promote lacrimal passage epithelium functional rehabilitation, prevent cicatrization, long-term effect is good, relapse rate is low, the advantage such as to degrade voluntarily, but there is the too fast problem of degradation speed in the application in this product of clinical discovery, the treatment cycle of Lacrimal Passage Block is generally 2 to 3 months, and this product just degrades after implanting lacrimal passage for 15 ~ 20 days, degrade too fast, can not meet the needs of Lacrimal Passage Block, affect therapeutic effect.
Utility model content
For solving in above-mentioned prior art existing problem, this utility model provides one to have Regeneration and Repair function, and degradation time meets clinical needs, the suitability and the better degradable amniotic membrane lacrimal passage recovery support of safety.
This utility model adopts following technical scheme to realize: a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body, described rack body is made up of degradable biomaterial, and one end of described rack body is connected with medical suture, and the outer wall of described rack body is enclosed with bioamnion.
Preferably, described rack body has the less taper end of the larger butt end of diameter, diameter and the transitioning end being connected described butt end and described taper end, and described medical suture is connected to described taper end.
Preferably, described butt end is tubulose, the outer wall of described butt end offers at least one conduction hole.
Preferably, described conduction hole be opened in described butt end outer wall near described transitioning end side.
Preferably, the diameter of described butt end is 2.5mm ~ 3.5mm, and hardness is shore A30 ~ 60, and length is 6cm ~ 9cm; The length of described taper end is 2cm ~ 3cm; The length of described transitioning end is 0.3cm ~ 0.6cm.
Preferably, described bioamnion is bonded in the outer wall of described rack body by medical science viscose glue.
Preferably, described degradable biomaterial is the one in polylactic acid, polyglycolic acid, polycaprolactone, PLA-PEG copolymer and PLGA.
Preferably, described bioamnion is the people's amniotic membrane through lyophilization process.
Preferably, the specification of described medical suture is 10-0 ~ 3, and diameter is 0.02mm ~ 0.699mm.
Compared with present technology, this utility model has following beneficial effect: this utility model structure is simple, has slowed down the degradation time of amniotic membrane, after outer field amniotic membrane degraded, part amniotic membrane degradation solution is attached on rack body, continues the effect playing amniotic membrane, meets the demand for the treatment of cycle; The rack body that degradable biomaterial is made remains the elasticity of silica gel tube, hot strength and tension force, slowly can degrade voluntarily, do not need tube drawing after treatment cycle, can not cause damage and secondary blocking to lacrimal passage tissue.
Accompanying drawing explanation
Fig. 1 is the structural representation of this utility model embodiment 1;
Fig. 2 is the structural representation of this utility model embodiment 2;
Fig. 3 is the structural representation of this utility model embodiment 3;
Fig. 4 is the structural representation of this utility model embodiment 4 and embodiment 5.
Detailed description of the invention
Be described in further detail below in conjunction with the Novel nose lacrimal passage recovery support of specific embodiment to a kind of degradable biological amniotic membrane of this utility model compound.
Embodiment 1
As shown in Figure 1, this utility model provides a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body 1, described rack body 1 is made up of polylactic acid, one end of described rack body 1 is connected with medical suture 2, the outer wall of described rack body 1 is enclosed with bioamnion 3, and described bioamnion 3 is bonded in the outer wall of described rack body 1 by medical science viscose glue; The diameter of described rack body 1 is 3.5mm, and hardness is shore A60, and length is 9cm; Described bioamnion 3 is the people's amniotic membranes through lyophilization process; Described medical suture 2 to be specifications be 3 II class suture, diameter is 0.6mm ~ 0.699mm.
Embodiment 2
As shown in Figure 2, this utility model provides a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body 1, described rack body 1 is made up of polyglycolic acid, one end of described rack body 1 is connected with medical suture 2, described rack body 1 is tubulose, outer wall offers several conduction holes 14, near described medical suture 2 side on the outer wall that described conduction hole 14 is opened in described rack body 1; The diameter of described rack body is 2.5mm, and hardness is shore A40, and length is 7cm; The outer wall of described rack body 1 is enclosed with bioamnion 3, and described bioamnion 3 is bonded in the outer wall of described rack body 1 by medical science viscose glue; Described bioamnion 3 is the people's amniotic membranes through lyophilization process; Described medical suture 2 to be specifications be 1 I class suture, diameter is 0.5mm ~ 0.599mm.
Embodiment 3
As shown in Figure 3, this utility model provides a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body 1, described rack body 1 is made up of PLGA, described rack body 1 has the less taper end 12 of the larger butt end of diameter 11, diameter and the transitioning end 13 being connected described butt end and described taper end, the diameter of described butt end 11 is 3.5mm, and hardness is shore A60, and length is 9cm; The length of described taper end 12 is 3cm; The length of described transitioning end 13 is 0.6cm, and described taper end 13 is connected with medical suture 2; The outer wall of described rack body 1 is enclosed with bioamnion 3, and described bioamnion 3 is bonded in the outer wall of described rack body 1 by medical science viscose glue; Described bioamnion 3 is the people's amniotic membranes through lyophilization process; The I class suture of described medical suture 2 to be specifications be 4-0, diameter is 0.2mm ~ 0.249mm.
Embodiment 4
As shown in Figure 4, this utility model provides a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body 1, described rack body 1 is made up of PLA-PEG copolymer, described rack body 1 has the less taper end 12 of the larger butt end of diameter 11, diameter and the transitioning end 13 being connected described butt end and described taper end, described butt end 11 is tubulose, the outer wall of described butt end 11 offers six conduction holes 14, near described transitioning end 13 side on the outer wall that described conduction hole 14 is opened in described butt end 11; The external diameter of described butt end 11 is 2.5mm, and internal diameter is 1.5mm, and hardness is shore A30, and length is 6cm; The length of described taper end 12 is 2cm; The length of described transitioning end 13 is 0.3cm, and described taper end 13 is connected with medical suture 2; The outer wall of described rack body 1 is enclosed with bioamnion 3, and described bioamnion 3 is bonded in the outer wall of described rack body 1 by medical science viscose glue; Described bioamnion 3 is the people's amniotic membranes through lyophilization process; The II class suture of described medical suture 2 to be specifications be 10-0, diameter is 0.02mm ~ 0.029mm.
Embodiment 5
As shown in Figure 4, this utility model provides a kind of degradable amniotic membrane lacrimal passage recovery support, comprise rack body 1, described rack body 1 is made up of polycaprolactone, described rack body 1 has the less taper end 12 of the larger butt end of diameter 11, diameter and the transitioning end 13 being connected described butt end and described taper end, described butt end 11 is tubulose, the outer wall of described butt end 11 offers several conduction holes 14, near described transitioning end 13 side on the outer wall that described conduction hole 14 is opened in described butt end 11; The external diameter of described butt end 11 is 3mm, and internal diameter is 2mm, and hardness is shore A50, and length is 8cm; The length of described taper end 12 is 2.5cm; The length of described transitioning end 13 is 0.5cm, and described taper end 13 is connected with medical suture 2; The outer wall of described rack body 1 is enclosed with bioamnion 3, and described bioamnion 3 is bonded in the outer wall of described rack body 1 by medical science viscose glue; Described bioamnion 3 is the people's amniotic membranes through lyophilization process; The II class suture of described medical suture 2 to be specifications be 2-0, diameter is 0.3mm ~ 0.339mm.
The foregoing is only preferred embodiment of the present utility model; not in order to limit this utility model; anyly be familiar with those skilled in the art in the technical scope that this utility model discloses, the change that can expect easily or replacement, all should be encompassed in protection domain of the present utility model.Therefore, the protection domain that protection domain of the present utility model should define with claim is as the criterion.
Claims (9)
1. a degradable amniotic membrane lacrimal passage recovery support, comprises rack body, it is characterized in that: described rack body is made up of degradable biomaterial, and one end of described rack body is connected with medical suture, and the outer wall of described rack body is enclosed with bioamnion.
2. degradable amniotic membrane lacrimal passage recovery support according to claim 1, it is characterized in that: described rack body has the less taper end of the larger butt end of diameter, diameter and the transitioning end being connected described butt end and described taper end, and described medical suture is connected to described taper end.
3. degradable amniotic membrane lacrimal passage recovery support according to claim 2, is characterized in that: described butt end is tubulose, the outer wall of described butt end offers at least one conduction hole.
4. degradable amniotic membrane lacrimal passage recovery support according to claim 3, is characterized in that: near described transitioning end side on the outer wall that described conduction hole is opened in described butt end.
5. degradable amniotic membrane lacrimal passage recovery support according to claim 2, is characterized in that: the diameter of described butt end is 2.5mm ~ 3.5mm, and hardness is shore A30 ~ 60, and length is 6cm ~ 9cm; The length of described taper end is 2cm ~ 3cm; The length of described transitioning end is 0.3cm ~ 0.6cm.
6. degradable amniotic membrane lacrimal passage recovery support according to claim 1, is characterized in that: described bioamnion is bonded in the outer wall of described rack body by medical science viscose glue.
7., according to the arbitrary described degradable amniotic membrane lacrimal passage recovery support of claim 1 to 6, it is characterized in that: described degradable biomaterial is the one in polylactic acid, polyglycolic acid, polycaprolactone, PLA-PEG copolymer and PLGA.
8., according to the arbitrary described degradable amniotic membrane lacrimal passage recovery support of claim 1 to 6, it is characterized in that: described bioamnion is the people's amniotic membrane through lyophilization process.
9., according to the arbitrary described degradable amniotic membrane lacrimal passage recovery support of claim 1 to 6, it is characterized in that: the specification of described medical suture is 10-0 ~ 3, and diameter is 0.02mm ~ 0.699mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420663134.7U CN204192798U (en) | 2014-11-06 | 2014-11-06 | A kind of degradable amniotic membrane lacrimal passage recovery support |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420663134.7U CN204192798U (en) | 2014-11-06 | 2014-11-06 | A kind of degradable amniotic membrane lacrimal passage recovery support |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204192798U true CN204192798U (en) | 2015-03-11 |
Family
ID=52650804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420663134.7U Active CN204192798U (en) | 2014-11-06 | 2014-11-06 | A kind of degradable amniotic membrane lacrimal passage recovery support |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204192798U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434536A (en) * | 2018-03-15 | 2018-08-24 | 广州聚明生物科技有限公司 | Lacrimal passage recovery support and preparation method thereof |
| CN109394398A (en) * | 2018-09-14 | 2019-03-01 | 江西瑞济生物工程技术股份有限公司 | A kind of degradable foldable bioamnion complex repairation bracket |
| CN114939190A (en) * | 2022-06-14 | 2022-08-26 | 健诺维(成都)生物科技有限公司 | Drainage tube material for treating glaucoma and preparation method thereof |
-
2014
- 2014-11-06 CN CN201420663134.7U patent/CN204192798U/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108434536A (en) * | 2018-03-15 | 2018-08-24 | 广州聚明生物科技有限公司 | Lacrimal passage recovery support and preparation method thereof |
| CN108434536B (en) * | 2018-03-15 | 2021-03-12 | 广州聚明生物科技有限公司 | Lacrimal passage repair stent and preparation method thereof |
| CN109394398A (en) * | 2018-09-14 | 2019-03-01 | 江西瑞济生物工程技术股份有限公司 | A kind of degradable foldable bioamnion complex repairation bracket |
| CN114939190A (en) * | 2022-06-14 | 2022-08-26 | 健诺维(成都)生物科技有限公司 | Drainage tube material for treating glaucoma and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pabari et al. | Nerve conduits for peripheral nerve surgery | |
| Brennan et al. | Antibacterial activity within degradation products of biological scaffolds composed of extracellular matrix | |
| CN204192798U (en) | A kind of degradable amniotic membrane lacrimal passage recovery support | |
| Teh et al. | A review on the use of hyaluronic acid in tympanic membrane wound healing | |
| Fishman et al. | Stem cell-based organ replacements—airway and lung tissue engineering | |
| JP2018534113A (en) | System and method for generation of gastrointestinal tissue | |
| CN104056297A (en) | Polylactic acid-based composite material surgical medical film and preparation method thereof | |
| CN101234041A (en) | Atrial septal defect plugging device knitted by degradable material | |
| Czaja et al. | Biomedical applications of microbial cellulose in burn wound recovery | |
| CN204193131U (en) | A kind of novel degradable bioamnion lacrimal passage recovery support | |
| CN105534640A (en) | Operation device and probe for fracture lacrimal duct anastomosis and lacrimal stent synchronous implanting | |
| CN204192801U (en) | A kind of Novel lacrimal recovery support of degradable biological amniotic membrane compound | |
| CN204193130U (en) | A kind of degradable biological amniotic membrane lacrimal passage recovery support | |
| Zhao et al. | The latest progress of tympanic membrane repair materials | |
| CN2812871Y (en) | Helical spring type artificial lacrimal passage | |
| CN108338844B (en) | Degradable skin expander | |
| Roth et al. | Endoscopic injection of submucosal bulking agents for the management of incontinent catheterizable channels | |
| CN109498963A (en) | A kind of bladder irrigation catheter | |
| CN104287877B (en) | The Novel lacrimal recovery support that a kind of degradable biological amniotic membrane is compound | |
| JP2019503819A (en) | System and method for the generation of gastrointestinal tissue in an anastomosis or physiological location | |
| CN209203727U (en) | Assembly type lacrimal dilating support | |
| CN203777102U (en) | Novel manual nasolacrimal duct | |
| CN203694193U (en) | Drainage catheter | |
| CN102908658B (en) | The electrospun polymer anti-adhesion fiber membrane that compliance is good | |
| CN201205308Y (en) | Nasal cavity lacrimal sac anastomotic support artificial tube |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 330000 No. 498, special road, hi tech Development Zone, Jiangxi, Nanchang Patentee after: JIANGXI RUIJI BIO-ENGINEERING TECHNOLOGY CO., LTD. Address before: 330029 Nanchang, Jiangxi Qingshan Lake District on the road, No. 108 Patentee before: Jiangxi Ruiji Bio-Engineering Technology Co., Ltd. |